These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1148 related items for PubMed ID: 30296931

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Rau M, Thiele K, Hartmann NK, Schuh A, Altiok E, Möllmann J, Keszei AP, Böhm M, Marx N, Lehrke M.
    Cardiovasc Diabetol; 2021 Jan 07; 20(1):6. PubMed ID: 33413355
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
    Kusunose K, Imai T, Tanaka A, Dohi K, Shiina K, Yamada T, Kida K, Eguchi K, Teragawa H, Takeishi Y, Ohte N, Yamada H, Sata M, Node K, CANDLE Trial Investigators.
    Cardiovasc Diabetol; 2021 Sep 14; 20(1):186. PubMed ID: 34521417
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.
    Lan NSR, Yeap BB, Fegan PG, Green G, Rankin JM, Dwivedi G.
    Int J Cardiovasc Imaging; 2021 Feb 14; 37(2):517-527. PubMed ID: 32959096
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
    Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K.
    Cardiovasc Diabetol; 2018 May 22; 17(1):73. PubMed ID: 29788955
    [Abstract] [Full Text] [Related]

  • 12. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, Zhang J.
    Cardiovasc Diabetol; 2021 Jan 25; 20(1):25. PubMed ID: 33494751
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: A sub-analysis of the PROTECT trial.
    Kusunose K, Imai T, Tanaka A, Doi M, Koide Y, Fukumoto K, Kadokami T, Ohishi M, Teragawa H, Ohte N, Yamada H, Sata M, Node K, PROTECT investigators.
    J Cardiol; 2024 Oct 25; 84(4):246-252. PubMed ID: 38378130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.